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Purpose of the study
The incidence of cervical cancer in HIV-infected women (a
consequence of persistent infection with oncogenic HPV)
did not decrease significantly since introduction of
HAART. We have evaluated the prevalence of oncogenic
HPV cervical infection and its clearance in a cohort of
HIV-infected women in the HAART era.
Methods
A systematic screening program of oncogenic HPV infec-
tion has been initiated in 2002 in HIV+ women; onco-
genic HPV was detected by Hybrid Capture II (Digene®)
amplification test performed on cervical smears. Women
were classified in three groups based on their screening
test: N = negative for HPV; P = positive HPV and no cervi-
cal high-grade dysplasic lesion; PN = positive HPV then
negative on follow-up (FU). The three groups were com-
pared in terms of demographics, CD4, viral load (VL),
HIV history and HAART.
Summary of results
488 women have been evaluated for the program: 181
were excluded because of past hysterectomy (51), current
or past high-grade cervical dysplasia or cancer (130). The
307 remaining women were classified as: group N (n =
157, 51%), P (n = 111, 36%), PN (n = 39, 13%). In uni-
variate analyses (chi-square test), positive screening for
HPV was associated with younger age (34 years vs. 38
(N+PN), p = 0.005), shorter FU for HIV infection (79
months (m) vs. 104, p = 0.0002) and lower median CD4
count both at the time of HPV screening and at the most
recent FU (335 vs. 452/μL, p < 0.0001 and 427 vs. 528, p
= 0.011). There was a trend for more women of African
origin in the P group (90% vs. 82% in N+PN, p = 0.08).
Although 80% of women in each group were treated with
HAART and 67% had a VL <50 cp/ml, treatment duration
was significantly shorter in HPV-infected women (group P
: 53 m vs. 81 (N+PN), p < 0.0001). This remained statisti-
cally significant when comparing women with persistent
HPV infection on two consecutive screenings (n = 44)
with women who cleared their infection (group PN, n =
39) (53 m vs. 90, p = 0.013).
In multivariate analysis (logistic regression), only lower
median CD4 count at time of first HPV screening
remained significantly associated with presence of HPV (p
= 0.0152).
Conclusion
Cervical infection with oncogenic HPV remains a signifi-
cant problem in HIV-infected women in the HAART era.
Whether this will induce an increase of cervical cancer
incidence in aging cohorts of HIV+ women remains
unknown. As previously described, CD4 level is signifi-
cantly associated with the risk of presence of oncogenic
HPV. Long-term impact of HAART on the natural history
of oncogenic HPV deserves further evaluation.
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